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Drug monitoring of biofluids is often time consuming and prohibitively expensive. Analysis of dried blood
spots offers advantages, such as reduced sample volume, but depends on extensive sample preparation
and the presence of a trained lab technician. Paper spray mass spectrometry allows rapid analysis of
small molecules from blood spots with minimal sample preparation, however, plasma is often the pre-
ferred matrix for bioanalysis. Plasma spots can be analyzed by paper spray MS, but a centrifugation step
to isolate the plasma is required. We demonstrate here the development of a paper spray cartridge con-
taining a plasma fractionation membrane to perform automatic on-cartridge plasma fractionation from
whole blood samples. Three commercially available blood fractionation membranes were evaluated
based on: 1) accuracy of drug concentration determination in plasma, and 2) extent of cell lysis and/or
penetration. The accuracy of drug concentration determination was quantitatively determined using high
performance liquid chromatography–mass spectrometry (HPLC–MS). While the fractionation mem-
branes were capable of yielding plasma samples with low levels of cell lysis, the membranes did exhibit
drug binding to varying degrees, as indicated by a decrease in the drug concentration relative to plasma
obtained by centrifugation. Using the membrane exhibiting the lowest binding, we developed a compos-
ite paper spray cartridge incorporating the selected fractionation membrane. Quantitative analysis of the
plasma samples by paper spray MS yielded results similar to those found with HPLC–MS, but without the
need for offline extraction or chromatography.
 2016 The Association for Mass Spectrometry: Applications to the Clinical Lab (MSACL). Published by
Elsevier B.V. This is an open access article under the CCBY license (http://creativecommons.org/licenses/by/
4.0/).1. Introduction
Monitoring biofluid drug concentration is important for a num-
ber of applications. Pharmaceuticals, for example, sometimes
require that concentrations be maintained within patient-specific
ranges to effect desired outcomes and, if possible, avoid toxicity.
Since individuals metabolize drugs at variable rates [1] it would
be useful to routinely monitor drug concentrations to ensure opti-
mal efficacy. Current methods that analyze whole blood require
time-consuming sample preparation. Whole blood also requires
special handling and refrigeration during transit. Because of these
factors, therapeutic drug monitoring is often prohibitively expen-
sive. Many fields in which small molecules are being monitored,
such as forensics and toxicology, are faced with a similar problem.
To address this need, there exists a continual push to develop rapid
and cost effective analytical techniques that require minimal sam-
ple handling and preparation.In 2010, paper spray mass spectrometry (PS-MS) emerged as a
facile technique requiring minimal sample preparation [2,3]. PS-
MS is an ambient ionization technique in which the sample is con-
tained on a paper substrate. The paper is placed in front of the
atmospheric pressure inlet of a mass spectrometer, and solvent is
eluted through the sample, extracting the analytes [4]. A high volt-
age applied to the paper generates a plume of charged droplets,
which produce a mass spectrum characteristic of (electrospray ion-
ization) ESI [2]. PS-MS has been demonstrated as a capable method
for the analysis of biofluids, such as blood and urine [2,3,5,6].
Direct analysis of blood spots reduces sample preparation and
minimizes the volume of sample required. Because of its simplic-
ity, PS-MS has potential for point-of-care analysis [7–9]. Dried
blood spots do not require the special handling or refrigeration of
whole blood samples. Thus, even if a point-of-care option is
unavailable, the sample could be shipped as a dried spot. In addi-
tion, analyte stability is generally enhanced in a dried blood matrix
[10,11]. PS-MS has been shown to be useful in the quantitation of a
wide variety of pharmaceuticals including immunosuppressive
drugs, such as tacrolimus and cyclosporine [12,13], as well as illicit
drugs [14–16].
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MS is a lower selectivity caused by a lack of chromatography, and a
lower sensitivity caused by matrix effects [17]. These disadvan-
tages can be partially ameliorated via ion mobility [18], on-
cartridge pre-concentration via solid phase extraction (SPE) [19],
solid-phase microextraction (SPME) in which a spray substrate is
immersed in a large sample volume [20,21], and alternative sub-
strates that improve detection for particular analytes [22–26].
One limitation of dried blood spot analysis is that it is the ana-
lyte concentration in plasma, not whole-blood, that is often desired
[27]. In general, the use of plasma, instead of blood, is more readily
accepted in pharmacokinetic studies [28]. This is especially true for
anti-psychotic drugs where drug plasma concentration correlates
to blocked receptors and efficacy [29]. Another concern is inaccu-
racy caused by a variable hematocrit [30]. Centrifugation, the typ-
ical method of obtaining plasma from whole blood, adds another
step in the analysis and also requires a dedicated piece of equip-
ment. Several methods for obtaining plasma from whole blood,
without resorting to centrifugation, have been reported and range
from acoustics [31] to labyrinth-like mazes [32]. While effective,
these methods are complex and may not be feasible for incorpora-
tion as part of a disposable collection device. Blood fractionation
membranes offer another potential solution. A blood fractionation
card has been described that is able to obtain plasma from capillary
blood in a timely manner with negligible lysis [33]. Another recent
study found that two different fraction membranes were capable of
obtaining plasma from whole blood and yielding accurate and pre-
cise analytical results for the drug guanfacine [34]. Another tech-
nique for obtaining plasma for colorimetric assays employed
agglutination of red blood cells using paper treated with antibod-
ies, which allowed isolation of plasma from the agglutinated cells
[35].
Paper spray can be used to analyze dried plasma spots. For
example, a paper spray cartridge was developed with an integrated
solid-phase extraction column to perform analyte pre-
concentration for analysis of plasma samples [19]; however, this
method required centrifugation. Here, we investigate the use of
several plasma separation membranes for small molecule drug
analysis using both HPLC- and paper spray MS/MS. Our goal is to
develop an inexpensive cartridge for rapid, direct analysis of
plasma obtained from a drop of whole blood. Using HPLC–MS/
MS, three commercially available blood fractionation membranes
were evaluated based on their ability to obtain hemolysis-free
plasma without altering small molecule drug concentrations. The
membranes were incorporated into a simple paper spray cartridge
to enable direct plasma analysis after application of a drop of
whole blood. Addition of agglutinating agents to the membranes
was also investigated to determine if they could improve blood
fractionation without interfering with drug detection.Fig. 1. Example membrane configurations for plasma fractionation from whole
blood. Sample punches are dyed green here for contrast. (A) Sample holder for the
vivid membrane shown left to right: holder with the sample punches, 13 mm
square of vivid membrane, and closed holder with membrane inside (B) Noviplex
fractionation card with sample punches in place. (C) Diagram of delrin tube used to
contain the 4 squares of CytoSep membrane (left) and delrin tube inside the holder
with the CytoSep membranes already in the tube (right).2. Materials and methods
2.1. Materials
All drugs and their stable isotopic labels (SIL), except atenolol
D7, were obtained from Cerilliant (Round Rock, TX). Atenolol D7
was obtained from CDN isotopes (Pointe-Claire, QC, Canada) as a
powder (P98% purity). HPLC-grade methanol, acetonitrile, formic
acid and acetic acid came from Fisher Scientific (Waltham, MA).
Five individual donor human blood samples came from Innovative
Research in K2EDTA-treated vials (Novi, MI). NoviPlex cards were
obtained from Novilytic (West Lafayette, IN), while CytoSep and
Vivid blood fractionation membranes were obtained from the Pall
Corporation (Port Washington, NY). The holder used to contain the
Vivid membrane was 3D printed using a Stratasys Objet 30 prousing VeroBlue photopolymer (Eden Prairie, MN). The paper spray
cartridges and other sample holders were machined out of Delrin
and HDPE plastic, respectively (McMaster-Carr) (Elmuhurst, IL)
on a bench-top mini milling machine (Sherline – Vista, CA). What-
man grade 31 ET chromatography paper was used for the spray
substrate and sample punches (GE Healthcare Life Sciences – Pitts-
burgh, PA). Human fibrinogen (50–70% protein), alum (aluminum
potassium sulfate dodecahydrate P98% purity), carbamazepine
powder (P98% purity), and NaCl were obtained from Sigma-
Aldrich (St. Louis, MO).
2.2. Plasma separation
As shown in Fig. 1, each membrane required different experi-
mental parameters to obtain extracted plasma. Sample punches
consisted of 3 mm punches of Whatman 31ET filter paper. The
Vivid GR membrane, shown in Fig. 1A, was prone to ripping, so a
special holder was made to contain the punches and a
13 mm  13 mm membrane. When the top piece of the holder
was put into position, it forced the membrane into a bowl shape
to hold a 40 lL blood sample while plasma wicked through to 3
sample punches over the course of 3 min. The NoviPlex plasma
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self-contained sampling device; the cards were used as designed,
except the sample collection disc in the NoviPlex card was replaced
with 3 of the same punches used in our other experiments. Frac-
tionation with the NoviPlex card entailed spotting 30 lL of whole
blood onto the top layer and allowing 3 min for plasma to wick
through to the sample punch below. The CytoSep membrane was
assembled inside a disposable tube by inserting four 5 mm  5 mm
squares of grade 1660 membrane, one at a time, as shown in
Fig. 1C. Four stacked membranes were required to yield improved
plasma fractionation. The disposable insert was a 9 mm length of
Delrin tubing (3.175 mm inner diameter) with a piece of wax paper
with a small hole in it glued over the bottom-end between the sep-
aration membrane and the collection disc. To obtain plasma, the
insert containing the membranes and wax paper was placed in a
tightly fitted HDPE holder with a sample punch beneath it, as
shown in the picture on the right in Fig. 1C. Whole blood was
applied to the top of the insert and 15 min was allowed for the
plasma to wick through to the sample punch. For each sample,
the wet mass of the sample punch was obtained using a microgram
scale and the plasma mass was determined by subtracting the
mass of the paper punch.
2.3. Sample preparation
The experimental samples for HPLC–MS/MS were prepared in
five different lots of blood at two concentrations: 1.5 lg/mL and
0.3 lg/mL for each drug. Each blood sample was taken through
the three different membrane fractionation methods in triplicate.
Drug stock solutions were diluted to working solutions in
0.6 mg/mL aqueous saline before being spiked into whole blood
to minimize solvent-based cell lysis. All spiked blood samples
had a maximum methanol content of 1.5% (v/v). Samples were
incubated at least 1 h at 37 C prior to fractionation and were
applied to the membrane fractionation apparatus while still warm.
The plasma punches were dried for 1 h at room temperature in
open air. Plasma control samples were prepared by centrifuging
an aliquot of the blood samples at 1500 rpm for 30 min.
Calibrators and calibration verification standards were prepared
in drug-free plasma pooled from 5 blood samples. The calibration
curve was prepared by spiking the pooled plasma with 0.03, 0.1,
0.3, 1 and 3 lg/mL each of atenolol, carbamazepine, fentanyl, nor-
triptyline, and methadone. A calibration verification sample was
prepared separately at 1 lg/mL. Calibrators and calibration verifi-
cation samples were spotted on paper punches identical to those
used for the fractionated samples. The paper punches contained
2.3 mg of the calibration samples, which corresponded to the aver-
age wet mass of plasma obtained using the three different plasma
fractionation membranes. An analytical balance was used to mea-
sure the mass of plasma for both the calibrators and the membrane
fractionated samples; these masses were required to normalize the
plasma volume of the HPLC–MS calibrators (see next section). Cal-
ibrators were run in duplicate, and a calibration verification stan-
dard was run every 10 samples.
To determine if PS-MS/MS could be used to obtain quantitative
results similar to those of HPLC–MS/MS, plasma extracted using
the fibrinogen-treated membranes was compared to centrifuged
plasma samples. The curve and samples were prepared as described
for the HPLC–MS/MS experiments. The samples came from a single
lot of blood with 6 replicates for the membrane separated samples
and 5 replicates for the centrifuged control samples.
2.4. HPLC–MS/MS
Dried sample punches were transferred to a 500 lL centrifuge
tube containing 100 lL of extraction solvent (15% methanol by vol-ume in water containing 0.1 lg/mL each of atenolol D7, carba-
mazepine D10, fentanyl D5, nortriptyline D3 and methadone D3).
Samples were vortexed for 30 min. The sample punches were then
removed and the solutions were centrifuged at 3000 rpm for 5 min.
From each sample, an 80 lL aliquot was transferred to an HPLC vial
for analysis. Analysis was carried out using an Agilent G2226A
nanopump and G1379A degasser with an Agilent G1329A
autosampler (Agilent Technologies, Santa Clara, CA) equipped with
a hypersil gold C18 column (Thermo Scientific, San Jose, CA) cou-
pled to a Thermo Scientific LTQ XL mass spectrometer. The sample
volume injected was 15 lL. The HPLC separation was a gradient
elution (Solvent A was water with 0.01% formic acid, solvent B
was methanol with 0.01% formic acid) at 200 mL/min. The gradient
was as follows: 15% Solvent B (2 min), followed by a linear increase
to 80% Solvent B over 2 min, then to 95% over 1.2 min. Solvent B
was held at 95% methanol for 4.5 min. The column was re-
equilibrated between runs for 5 min with 400 lL/min of 15% Sol-
vent B. MS was conducted in positive ion mode using electrospray
ionization (ESI). The sheath gas was set to 20 while the auxiliary
gas was set to 5. The spray voltage was 4.5 kV. The instrument
was operated in MS/MS mode. The area under the curve was deter-
mined for a unique fragment of the [M+H]+ ion for each analyte and
ratios were determined by dividing the peak area for the analyte by
the peak area for the SIL. The slope and y-intercept of the curve for
each drug was found using 1/x weighted least squares [36]. Analy-
sis of all samples obtained from the three different membranes
was performed in one continuous run based off a single curve.
Because each of the three membrane types yielded a different mass
of plasma, final concentrations obtained from the calibration curve
were normalized based on the average mass of plasma obtained for
the each membrane type using Eq. (1):
Cf ¼ Ci McalibrationMsample
 
ð1Þ
where Cf is the final determined concentration, Ci is the concentra-
tion calculated without normalizing the mass of the plasma calibra-
tors, Mcalibration is the average mass of plasma spotted for the
calibrators, and Msample is the average mass of plasma obtained for
a particular plasma fractionation method. Mcalibration was 2.3 mg.
Msample values were 2.2 mg, 2.8 mg, and 1.5 mg for the cytosep,
vivid, and the noviplex membranes, respectively.
Limits of detection (LOD) for both paper spray and HPLC–MS/
MS were estimated using the formula LOD = (3 * sB)/m, where sB
is the standard error of the intercept and m is the slope of the cal-
ibration line.2.5. Paper spray analysis
Plasma fractionation and PS-MS was carried out on a custom-
built spray cartridge shown in Fig. 2. The removable insert was
used for trials involving the CytoSep membrane as described
above. The blood sample was applied to the removable tube, which
contained the fractionation membranes in contact with a sample
punch below the tube. When the punch was saturated after about
15 min, the tube insert was removed and discarded. An aliquot of
0.5 lg/mL SIL in methanol, with a volume equivalent to the aver-
age mass of extracted plasma, was spotted onto the dried plasma
punch. After drying, the paper disc containing the plasma sample
was pushed down onto the spray substrate.
Analysis was performed by positioning the cartridge in front of
an LTQ XL mass spectrometer with the paper tip 2.5 mm away
from the MS inlet. A 30 lL aliquot of spray solvent was pipetted
on top of the sample disc, where it wicked through the sample
and onto the spray substrate. The spray solvent was 95:5:0.01
methanol:water:acetic acid, except for cotinine samples, for which
 Blood from a finger stick 
Removable insert 
containing membrane 
3 mm sample punch 
Conductive wire 
Spray substrate 
Fig. 2. Schematic for paper spray cartridge with removable blood fractionation
insert. The plastic is Delrin and the sample punch and spray substrate are Whatman
grade 31 ET filter paper.
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4.5 kV was applied for 60 s, via the wire contacting the spray sub-
strate, to initiate the plume of ions. Analysis was carried out in MS/
MS mode using the base peak fragment of the [M+H]+ for quantita-
tion. For experimental purposes, one spray cartridge was re-used
for each analysis and sample preparation was conducted in a block
of plastic with holes as shown in Fig. 1C. Between runs, the car-
tridge was cleaned with methanol and the spray substrate was
replaced.2.6. Determining hematocrit and membrane induced hemolysis
The hematocrit was determined for each of the five lots of
blood by filling a 25 mm segment of a borosilicate glass capillary
(0.86 mm inner diameter Sutter Instrument, Novato, CA) with
blood followed by sealing the tube with paraffin wax and cen-
trifuging at 1500 rpm for 30 min. Hematocrit was calculated by
measuring the packed cell volume relative to the total sample
volume. The extent of red blood cell lysis and penetration in
the membrane fractionated plasma samples was determined by
measuring the absorbance of the sample from the extracts used
for HPLC-MS/MS at 413 nm using a Thermo Scientific NanoDrop
2000 spectrophotometer. A calibration curve was created by mix-
ing whole blood (a mix of equal parts of all 5 lots of blood) with
centrifuged plasma to make calibrants ranging from 0.45% to 9%
(v/v) cellular material in plasma. Blood cell content calibrators
were dried and extracted as described for the experimental
samples.Table 1
Average and 95% confidence interval for the wet plasma mass obtained for each
membrane (N = 30 across 5 blood lots) and average and 95% confidence interval red
blood cell content in the plasma (N = 5 for each method except Vivid, which had 4 due
to a small amount of leaked blood in the holder).
Fractionation
membrane
Mass of plasma obtained
(mg)
Red blood cell % (v/
v)
CytoSep grade 1660 2.2 ± 0.4 6 ± 2
Vivid GR 2.82 ± 0.06 0.22 ± 0.09
Noviplex 1.53 ± 0.04 0.8 ± 0.22.7. Membrane treatment to improve plasma separation
Fibrinogen concentrations ranging from 20 to 1000 lg/mL were
tested for separation efficiency and potential drug binding on the
CytoSep membrane. Fibrinogen solutions were spotted onto each
membrane in the stack in four aliquots of 5 lL allowing roughly
an hour between aliquots for drying at room temperature. The
non-protein based agglutinating agent, alum, was also tested by
treating different arrangements of 3 CytoSep membranes treated
with varying combinations of alum solutions ranging in concentra-
tion from 20 to 60 mg/mL. In the final configuration only the top
membrane was treated with 5 lL of 40 mg/mL alum solution.3. Results and discussion
3.1. Hematocrit, plasma mass and lysis/cell penetration
Three commercially available plasma separation membranes
were evaluated for their ability to obtain reproducible amounts
of red blood cell-free plasma (Table 1). Five lots of human blood,
with hematocrits ranging from 45 to 54%, were evaluated. The
average mass of plasma obtained for each membrane was calcu-
lated from 30 samples (6 replicates from each lot of blood) and
the % volume of red blood cells was determined based on 5 sam-
ples (1 replicate from each lot). Both the Vivid GR and Noviplex
card showed good plasma fractionation with a total red blood cell
content below 1% (v/v). The Cytosep grade 1660 membrane
stacked 4 high showed noticeably reduced separation, most likely
due to the lateral flow characteristic of the membrane.
3.2. Assessment of drug binding
Drug binding was evaluated by measuring the drug concentra-
tion of the plasma obtained by membrane filtration and determin-
ing the % decrease relative to plasma obtained by centrifugation
(Table 2). Calibrators and calibration verification samples were
prepared directly in plasma to ensure a known plasma concentra-
tion. The experimental samples were prepared in whole blood, as
described in the Materials and Methods section, to allow the drugs
to distribute between the blood cells and the plasma. Drug quanti-
tation was performed using HPLC–MS/MS. The raw concentration
data can be found in Supplementary Table 1.
Both the Vivid GR and the NoviPlex membranes caused a mea-
surable and significant decrease in the concentration for all five
drugs. The CytoSep membrane showed a noticeable decrease for
three drugs, but not for atenolol and carbamazepine. The presumed
cause of the decrease in drug concentration in membrane-
fractionated plasma is drug adsorption to the membrane. For
example, the Vivid membrane is polysulfone–based, and it has
been shown in several studies that polysulfone-based membranes
can cause a decrease in drug concentration in the blood when used
for dialysis [37,38].
3.3. Membrane treatment to improve plasma separation
The CytoSep membrane showed the lowest amount of drug
binding, but also resulted in the highest level of red blood cell con-
tent in the collected plasma sample. We investigated methods for
improving the plasma fractionation efficiency from this mem-
brane. Previous work showed that agglutinating cells allowed for
plasma to be separated from blood cells in paper-based devices
[35]. However, this method employed anti-A and anti-B antibodies
to effect the agglutination, and thus its application is limited to
blood types which express these antigens, and would not be effec-
tive in causing agglutination of type O blood [35]. We chose alter-
native agglutination agents: fibrinogen, a key protein in the
coagulation cascade [39], and alum [40]. Fibrinogen and alumwere
Table 2
The average % decrease in drug concentration relative to the concentration found in centrifuged plasma for three commercially available membranes at two concentrations.
Drug Concentration CytoSep Vivid Noviplex
Atenolol 0.3 lg/mL 13% 36% 33%
1.5 lg/mL 0% 36% 30%
Carbamazepine 0.3 lg/mL 17% 65% 51%
1.5 lg/mL 8% 71% 62%
Fentanyl 0.3 lg/mL 31% 76% 31%
1.5 lg/mL 28% 79% 31%
Methadone 0.3 lg/mL 55% 66% 50%
1.5 lg/mL 42% 45% 36%
Nortriptyline 0.3 lg/mL 78% 57% 29%
1.5 lg/mL 76% 64% 30%
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section above and allowed to dry before assembly of the insert.
Fibrinogen concentrations ranging from 20 to 1000 lg/mL were
tested. Fibrinogen concentrations of 75 lg/mL or greater were
deemed unacceptable, because they showed measurable drug
binding for the initial test set of drugs. The 50 lg/mL fibrinogen-
treated membranes showed improved cell lysis/penetration of
approximately 3% compared to approximately 6% for the untreated
membrane. Concentrations less than 50 lg/mL showed minimal
improvement. Hence, the 50 lg/mL fibrinogen-treated membrane
was selected for further evaluation.
Similarly, different concentrations of alum were evaluated for
their effects on separation efficiency. However, it was found that
the amount of alum required to improve the plasma separation
also yielded irreproducible amounts of plasma on the collection
disc. A lower concentration (i.e., 40 mg/mL instead of 60 mg/mL)
of alumwas chosen for further testing, as described in the methods
section, even though the separation efficiency was similar to that
of the untreated membrane. This testing was performed to evalu-
ate if a non-protein based agglutination agent would have a notice-
able impact on the binding properties of the drugs.3.4. Evaluation of errors from drug binding and cell lysis
A selection of drugs with varying logP and KB/P values were
tested to better understand the binding characteristics of the trea-
ted and untreated CytoSep membrane, as well as the errors caused
by blood cell lysis. Plasma samples were applied to the membrane
fractionation device in addition to whole blood samples to evaluate
the hypothesis that plasma samples could be used to evaluate
membrane drug binding. This would be advantageous because
using plasma samples to evaluate drug binding removes the com-
plicating effects of red blood cell lysis/penetration. The results are
shown in Table 3.Table 3
Deviation in drug concentration in plasma obtained using CytoSep grade 1660 membrane
centrifuge. Drug concentrations ranged from 250 to 1000 ng/mL. NS indicates that the differ
not statistically significant (p > 0.05).
Drug logP KB/P Deviation for plasma applied to
untreated membrane
Deviation for b
untreated mem
Selegiline 3.08 1.7 5% NS 26%
Chlorpheniramine 3.74 1.34 5% NS 31%
Atenolol 0.57 1.07 8% NS 2% NS
Carbamazepine 2.1 1.06 13% NS 5% NS
Fentanyl 4.02 0.97 3% NS 31%
Cotinine 0.39 0.88 4% NS 15%
Alprazolam 2.23 0.78 5% NS 14%
Methadone 4.14 0.75 10% NS 51%
Diazepam 2.63 0.58 15% NS 4% NSNone of the nine drugs tested exhibited significant binding
when plasma samples were applied to the membrane. However,
when whole blood was applied to the membrane, rather than
plasma, six of the drugs showed a measurable decrease in analyte
concentration. The two most probable sources of error are cell
lysis/penetration or increased membrane-binding from blood com-
pared to plasma. If cell lysis/penetration was the principal source
of error in blood, then the error after passing through the mem-
brane should be negative for drugs with a KB/P < 1, positive for
drugs with a KB/P > 1, and minimal for drugs with a KB/P close to
1. The drug concentration deviation did not correlate with the KB/
P, however. For example, selegiline and chlorpheniramine have a
KB/P well above 1, but showed a significant decrease in blood con-
centration after passing through the membrane. Methadone had a
negative error, but it was much greater in magnitude than would
be expected based on the measured levels of cell lysis/penetration
and its KB/P. We hypothesize that the error is caused rather by
higher levels of drug binding to the membrane in blood samples
compared to plasma. One possible reason for the higher levels of
membrane drug binding in blood samples compared to plasma
samples is the slower passage of blood samples through the mem-
brane. Plasma samples pass through the membrane considerably
faster due to their lower viscosity and because the membrane is
not clogged by blood cells. The decreased extraction time (roughly
5 times shorter than with whole blood) could lead to less binding
due to the shorter interaction time with the membrane. Another
possibility is that the cellular material in the whole blood samples
contributes to drug binding as it accumulates on the membrane.
Either way, plasma is not a suitable matrix for evaluating drug
binding by the fractionation membranes.
Table 3 also shows the logP (octanol-water) for each analyte. All
of the drugs with a logP of 3 or greater exhibited negative devia-
tions of 20% or more against the untreated membrane in whole
blood samples. All the drugs with a logP below 3, on the other(both untreated and treated with alum or fibrinogen) relative to plasma obtained via
ence between the results for the membrane-fractionated and centrifuged plasma were
lood applied to
brane
Deviation for blood applied to
fibrinogen membrane
Deviation for blood applied
alum membrane
43% 21%
46% 18%
8% NS 4% NS
3% NS 10% NS
24% 31%
19% 0% NS
11% 37%
45% 13%
17% 6% NS
Table 4
Calibration curve R2, LOD, and the deviation of the plasma samples obtained by membrane-fractionation compared to centrifugation. Membrane-fractionated plasma was
compared to centrifuged plasma at two levels (0.3 and 1.5 lg/mL of atenolol or carbamazepine). Results obtained using both HPLC–MS/MS and paper spray-MS/MS for the same
experiment are shown for comparison. NS indicates that the difference between the membrane fractionated and centrifuged plasma samplers were not statistically significant
(p > 0.05).
Atenolol Carbamazepine
PS-MS/MS HPLC–MS/MS PS-MS/MS HPLC–MS/MS
Calibration curve R2 0.983 0.982 0.989 0.995
LOD from plasma (lg/mL) 0.04 0.03 0.03 0.02
Deviation between membrane fractionated and centrifuged plasma at 0.3 lg/mL 10% (NS) 2% (NS) 4% (NS) 9% (NS)
Deviation between membrane fractionated and centrifuged plasma at 1.5 lg/mL 9% (NS) 0.4% (NS) 10% (NS) 8% (NS)
B.J. Bills, N.E. Manicke / Clinical Mass Spectrometry 2 (2016) 18–24 23hand, deviated by 15% or less. This suggests that drugs with a KB/P
close to 1 and a logP below 3 are the least likely to be biased by
membrane fractionation.
Membranes treated with agglutinated agents were also evalu-
ated. Whole blood samples were applied to the treated mem-
branes, and the concentration in the fractionated plasma was
compared to centrifuged plasma from the same source. Although
fibrinogen significantly decreased the amount of cell lysis/penetra-
tion, it did not improve the analyte error. In two cases, selegiline
and chlorpheniramine, larger negative error was observed. This
could be due to the lower amount of cell lysis/penetration in the
fibrinogen-treated membrane; for drugs with KB/P values > 1, the
error from cell lysis/penetration should partially offset the error
from drug binding. For the alum-treated membranes, the amount
of cell lysis/penetration was not significantly different than the
untreated membrane. There was a measurable decrease in analyte
binding relative to the untreated membrane for two of the drugs
(cotinine and methadone), but one of the drugs (alprazolam)
showed increased binding.3.5. Quantitative analysis by paper spray MS/MS
We built a prototype paper spray cartridge incorporating a
plasma fractionation membrane (Fig. 2). A drop of blood applied
to the cartridge yields a plasma spot that can be analyzed directly
from the cartridge via paper spray MS without any additional sam-
ple preparation. To evaluate the ability of the method to quantify
plasma concentrations, blood samples containing atenolol and car-
bamazepine at concentrations of 0.3 and 1.5 lg/mL were prepared.
The plasma was then fractionated using the fibrinogen-treated
membrane inserts and compared to centrifuged plasma from the
same blood sample. An example paper spray calibration curve forFig. 3. Paper spray MS/MS calibration curve for carbamazepine. X-axis is the
concentration of drug spiked into the plasma. y-axis is a ratio of the instrument
response to the unlabeled drug to the isotopically labeled internal standard.carbamazepine is shown in Fig. 3. The results for the calibration
curves, the limits of detection, and the deviation obtained for the
membrane fractionated plasma samples, as compared to the cen-
trifuged plasma control samples, are shown in Table 4. HPLC–
MS/MS results for the same experiment are also shown in Table 4.
The raw concentration data, with standard deviations for both
HPLC–MS and PS-MS, can be found in Supplementary Tables 2
and 3, respectively. Comparing plasma obtained by centrifugation
to the on-cartridge membrane fractionation, the determined ate-
nolol and carbamazepine concentrations, as well as the limits of
detection, were not significantly different. The use of HPLC–MS/
MS rather than PS-MS/MS yielded similar results when comparing
membrane fractionation and centrifuged plasma samples as shown
in Table 4 and Supplementary Table 3. The PS-MS results, however,
were obtained without an extraction step (30–35 min) or a HPLC
run (around 14 min per sample). This significantly reduced the
amount of time and effort required to obtain the result.
Ideally, the paper spray cartridge would be able to deliver a
reproducible volume of plasma from poorly controlled blood sam-
ple volumes. We applied volumes of blood ranging from 30 to
50 lL to the treatedmembranes to determine if they yielded similar
masses of plasma. Over a range of 20 lL, the volume of blood had no
effect on the extracted volume of plasma (Supplementary Table 4).4. Conclusion
Three different membranes were evaluated for lysis and drug
binding in order to develop a disposable paper spray MS cartridge
to analyze a dried plasma sample obtained from a drop of whole
blood. The membranes were made from a variety of materials
ranging from polymers to natural and synthetic fibers. Two of
the three membranes, the Vivid polysulfone membrane and the
NoviPlex plasma fractionation card, exhibited noticeable amounts
of drug binding for each of the five drugs tested. The third mem-
brane, CytoSep, exhibited no significant binding for two of the
drugs, but did exhibit drug binding for others. While the CytoSep
membrane had the most favorable drug binding characteristics, it
showed the poorest fractionation efficiency, as measured by the
red blood cell content in the fractionated plasma. Overall, this
membrane could be used in quantitative analysis of drugs with a
logP less than three and a KB/P near unity, but is not a universal
solution.
This work was done with the intent of developing a simple
method for analyzing plasma from whole blood using paper spray
mass spectrometry. We have demonstrated a proof-of-concept
design for a simple paper spray cartridge to perform direct plasma
analysis from a drop of blood. Using this cartridge, plasma sample
could be obtained from an uncontrolled volume of whole blood,
and direct analysis could then be performed on the plasma sample
using paper spray MS without separate extraction or chromatogra-
phy steps. Quantitative analysis using the paper spray MS cartridge
was found to be comparable to extraction of dried plasma spots
followed by HPLC–MS/MS. However, unbiased results are only
24 B.J. Bills, N.E. Manicke / Clinical Mass Spectrometry 2 (2016) 18–24obtainable for membrane-fractionated plasma for a subset of drugs
due to the potential for drug binding and cell lysis. Further inves-
tigation is required to identify membrane materials that are cap-
able of sufficient plasma fractionation efficiency, while
minimizing non-specific drug binding.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.clinms.2016.12.
002.
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